Edwards Lifesciences Eyes $4 Billion Mark for 2018, Acquires Harpoon Medical
Coming off a very strong 2017, Edwards Lifesciences, Inc. has big plans for next year, as it will continue on its path to investing in breakthrough technologies and projects global sales to hit up to $3.9 billion. The company’s transcatheter aortic valve products are driving worldwide growth; transcatheter heart valve devices will see a $5+ billion global opportunity by 2021, thanks both to more awareness and improvements in the technology. The 2018 sales guidance expects sales to range between $3.5 and $3.9 billion, and the company provided sales guidance for the following areas:
- Transcatheter heart valve therapies: $2.1–$2.4 billion, $15 million of which from sales of transcatheter mitral and tricuspid therapies
- Surgical heart valve therapies: $810–$850 million
- Critical care technologies: $610–$650 million
Earlier this week Edwards Lifesciences also announced its acquisition of privately held Harpoon Medical, Inc., a manufacturer of products for degenerative mitral regurgitation. On December 1, Edwards paid $100 million in cash for the company.
“The unique beating-heart repair procedure for mitral valve patients complements Edwards’ comprehensive portfolio of treatments for structural heart disease, and reinforces our commitment to innovation in cardiac surgery,” said Bernard Zovighian, Edwards’ corporate vice president, surgical heart valve therapy in a company press release.
Related Articles
-
Leslie Trigg, CEO of Outset Medical, is the new Chair of The Medical Device Manufacturers Association (MDMA) Board of Directors.
-
Baxter Hillrom is recalling its WatchCare Incontinence Management System (IMS) following reports that the radiofrequency emissions (RF) from WatchCare devices may interfere with other medical devices.
-
The UK MHRA has published “Software and Artificial Intelligence as a Medical Device.” The guidance document assembles previous guidances and regulatory requirements for SaMD and AIaMD devices seeking commercialization in the UK market.
-
The MDDT program was developed in collaboration with the National Institutes of Health’s (NIH’s) National Institute of Drug Abuse (NIDA), National Institute of Dental Craniofacial Research (NIDCR) and National Cancer Institute (NCI) as a way for the FDA to qualify…
About The Author
MedTech Intelligence Staff
The MedTech Intelligence staff consists of freelance journalists and industry contributing writers with decades of experience in covering medical device issues under the categories of business, market trends, product development, quality, regulatory, and operations.
You can contact our writing staff via our Contact Page.